ANXA5 and cancer: A 48-h treatment with LPV (1 μg/ml, i.e., 1.6 μM) induced an increase in annexin-V–fluorescein isothiocyanate (FITC) labeling in 77.5±12.4% (n=4) of the cells, while a similar treatment did not induce significant labeling in the total cancer cell population (Figure 4a).